Form 4: Nuvalent CDO Exercises Options, Sells Shares

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NUVL), reported transactions involving Class A Common Stock.
• On January 29, 2026, Noci exercised stock options to acquire 5,500 shares of Class A Common Stock at an exercise price of $27.85 per share.
• Concurrently, Noci sold a total of 5,500 shares of Class A Common Stock in multiple transactions on January 29, 2026.
• The sales occurred at weighted average prices ranging from $100.95 to $103.39 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.
• Following these transactions, Darlene Noci directly beneficially owns 58,117 shares of Class A Common Stock and 108,829 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, it's a pre-planned transaction under a 10b5-1 plan, which is a routine part of executive compensation and financial management. The significant gain from option exercise is a positive for the executive.

Positives

• The exercise of stock options by a Chief Development Officer indicates a realization of value from their compensation package.
• The sale prices for the shares ($100.95 to $103.39) are significantly higher than the exercise price ($27.85), demonstrating a substantial gain for the insider.

Negatives

• The immediate sale of all shares acquired through option exercise, even if pre-planned, could be perceived as an insider taking profits rather than increasing their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Nuvalent, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that transactions executed under Rule 10b5-1 trading plans are a standard practice for corporate insiders. These plans allow executives to pre-arrange sales or purchases of company stock at a future date, providing an affirmative defense against claims of insider trading by demonstrating that the trades were not based on material non-public information. Such plans are common for managing personal financial planning and diversifying holdings.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider transactions is a widely accepted corporate governance practice across industries, including biotechnology and pharmaceuticals, where Nuvalent operates. This mechanism is consistent with best practices for executive compensation and personal financial management, similar to plans adopted by executives at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX).

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Development Officer, even if planned, could be viewed with slight caution, but the volume is not exceptionally large relative to the company's market capitalization. The transparency provided by the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of an equivalent number of shares. It does not reveal new material information about Nuvalent's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is consistent with an executive managing their personal equity holdings and compensation.

Keywords

Nuvalent, NUVL, Darlene Noci, Chief Development Officer, Insider Transaction, Form 4, Stock Options, 10b5-1 Plan, Equity Sales